Literature DB >> 10435091

Impact of chimeric immune receptor extracellular protein domains on T cell function.

S D Patel1, M Moskalenko, D Smith, B Maske, M H Finer, J G McArthur.   

Abstract

Chimeric immune receptors (CIR) encompass tumor- or virus-specific ligands or antibodies fused to the signaling domains of either the T cell receptor or Fc receptor. T cells expressing these receptors recapitulate the cytopathic effects mediated by the T cell receptor and allow the targeting of tumor or virus infected cells in an MHC-independent manner. With this technology, large numbers of T cells with redirected target specificity can be generated. To define the structural features of recombinant CIRs required for optimal function, a panel of five closely related CIRs with identical target specificity were generated. These receptors recognized HIVenv through the single chain Fv (scFv) of an anti-gp 120 antibody. These scFv-zeta receptors were constructed to include alternative extracellular spacer and transmembrane protein domains derived from members of the immunoglobulin supergene family. The effect of these alternative extracellular protein domains on receptor stability, antigen affinity and T cell activity was assessed. We demonstrate that modifying the extracellular protein domains of the anti-HIVenv CIRs significantly impacted receptor stability and substrate binding affinity and that these effects, and not simply the level of cell surface expression, correlated most strongly with changes in CIR-mediated killing. These studies will aid in the rationale design of recombinant CIRs for the immunotherapy of viral infections, cancer and other diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435091     DOI: 10.1038/sj.gt.3300831

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

Review 1.  Chimeric antigen receptor T-cell approaches to HIV cure.

Authors:  Anne-Sophie Kuhlmann; Christopher W Peterson; Hans-Peter Kiem
Journal:  Curr Opin HIV AIDS       Date:  2018-09       Impact factor: 4.283

Review 2.  Quarter Century of Anti-HIV CAR T Cells.

Authors:  Thor A Wagner
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

Review 3.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

4.  Genetically engineered T cells to target EGFRvIII expressing glioblastoma.

Authors:  Szofia S Bullain; Ayguen Sahin; Oszkar Szentirmai; Carlos Sanchez; Ning Lin; Elizabeth Baratta; Peter Waterman; Ralph Weissleder; Richard C Mulligan; Bob S Carter
Journal:  J Neurooncol       Date:  2009-04-23       Impact factor: 4.130

Review 5.  Next-generation CAR T cells to overcome current drawbacks.

Authors:  Stefan Lundh; Sayantan Maji; J Joseph Melenhorst
Journal:  Int J Hematol       Date:  2020-06-27       Impact factor: 2.490

6.  A mutant retroviral receptor restricts virus superinfection interference and productive infection.

Authors:  Meihong Liu; Maribeth V Eiden
Journal:  Retrovirology       Date:  2012-06-12       Impact factor: 4.602

7.  Engineering Chimeric Antigen Receptors.

Authors:  S V Kulemzin; V V Kuznetsova; M Mamonkin; A V Taranin; A A Gorchakov
Journal:  Acta Naturae       Date:  2017 Jan-Mar       Impact factor: 1.845

Review 8.  Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.

Authors:  Huan Shi; Meili Sun; Lin Liu; Zhehai Wang
Journal:  Mol Cancer       Date:  2014-09-21       Impact factor: 27.401

9.  A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.

Authors:  Daniel Schäfer; Janina Henze; Rita Pfeifer; Anna Schleicher; Janina Brauner; Nadine Mockel-Tenbrinck; Carola Barth; Daniela Gudert; Wa'el Al Rawashdeh; Ian C D Johnston; Olaf Hardt
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

Review 10.  The cGAS/STING Pathway: A Novel Target for Cancer Therapy.

Authors:  Yu Gan; Xiaoying Li; Shuangze Han; Qi Liang; Xiaoqian Ma; Pengfei Rong; Wei Wang; Wei Li
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.